Nordic Nanovector ASA (OSE: NANO) announces that Dr Lars Nieba has been
appointed interim Chief Executive Officer with immediate effect. Dr Nieba, who
is currently the Company's Chief Technology Officer, replaces Eduardo Bravo who
as of today has left Nordic Nanovector to pursue other career opportunities.

Dr Nieba joined Nordic Nanovector on 1 December 2019 from Bayer AG where he
served in various operational and strategic roles, Dr Nieba was most recently
responsible for driving Bayer's Chemistry, Manufacturing and Controls (CMC)
strategy for biologicals. He joined Bayer in 2016 following 13 years at F.
Hoffmann-La Roche Ltd., where he held various leadership roles in clinical,
operations, supply planning, biologics technology and technical business
development. Prior Dr Nieba worked for Cytos Biotechnology where he served as
Head of Therapeutic Vaccine Research.

Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München
and Institute for Biochemistry at the University of Zürich, and an Executive MBA
from the University of St. Gallen, Switzerland.

Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented: "The Board is very
pleased to appoint Lars Nieba as Nordic Nanovector's interim CEO. We believe
that his significant operational, development and product supply expertise will
be crucial as we work towards completing the PARADIGME study and prepare for the
planned filing for Betalutin® with the FDA. On behalf of the Board I would like
to thank Eduardo for his contribution as CEO."

For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector

Tel: +31 614672518
Email: janegberts@aol.com



Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting antibody-radionuclide-conjugate designed to advance the treatment of
non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet
medical need, representing a growing market forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin®
and intends to actively participate in the commercialisation of Betalutin® in
the US and other major markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements.  These
statements are based on management's current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking